title: Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.
abstract: In the contact phase of activation of the kinin-forming, intrinsic clotting, and fibrinolytic systems, high-molecular-weight kininogen acts as a cofactor for the activation of Factor XI, prekallikrein, and Hageman factor. One mechanism by which high-molecular-weight kininogen acts as a cofactor has been studied by using 125I-labeled Factor XI and prekallikrein in kaolin-activated normal human plasma and plasmas deficient in high-molecular-weight kininogen and Hageman factor. High-molecular-weight kininogen was found to be essential for normal binding and cleavage of both Factor XI and prekallikrein on the kaolin surface. Hageman factor was essential for cleavage but not for binding of Factor XI and prekallikrein to kaolin. In normal plasma 80% of the activated Factor XI remained surface-bound, whereas 80% of the kallikrein was not surface-bound. These findings are consistent with the hypothesis that, in the initial phase of contact activation, high-molecular-weight kininogen links both Factor XI and prekallikrein to the exposed surface where they are activated by surface-bound activated Hageman factor. Once activated, the Factor XI molecules remain localized at the site of activation, in contrast to the kallikrein molecules which are found largely in the surrounding plasma.
mesh_terms: D000328:Adult; D004789:Enzyme Activation; D005172:Factor XI / Q000302:isolation & purification / Q000378:metabolism*; D005175:Factor XII Deficiency / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D007610:Kallikreins / Q000378:metabolism*; D007704:Kininogens / Q000302:isolation & purification / Q000502:physiology*; D008970:Molecular Weight; D011288:Prekallikrein / Q000302:isolation & purification / Q000378:metabolism*; D011485:Protein Binding
chemical_list: D007704:Kininogens; D005172:Factor XI; D011288:Prekallikrein; D007610:Kallikreins
references.citation: J Clin Invest. 1975 Dec;56(6):1663-72
references.pmid: 127805
references.citation: J Clin Invest. 1977 Jun;59(6):1167-75
references.pmid: 864009
references.citation: Proc Natl Acad Sci U S A. 1976 Aug;73(8):2554-8
references.pmid: 1066663
references.citation: Proc Natl Acad Sci U S A. 1976 Nov;73(11):4179-83
references.pmid: 1069308
references.citation: J Clin Invest. 1975 Nov;56(5):1082-92
references.pmid: 1184736
references.citation: J Clin Invest. 1975 Dec;56(6):1650-62
references.pmid: 1202089
references.citation: J Lab Clin Med. 1976 Feb;87(2):327-37
references.pmid: 1245795
references.citation: J Exp Med. 1971 Oct 1;134(4):986-1004
references.pmid: 4106492
references.citation: Hoppe Seylers Z Physiol Chem. 1972 Oct;353(10):1591-606
references.pmid: 4119465
references.citation: Int Arch Allergy Appl Immunol. 1966;29(2):185-9
references.pmid: 4160044
references.citation: J Clin Invest. 1968 Dec;47(12):2608-15
references.pmid: 4302176
references.citation: J Clin Invest. 1972 Jul;51(7):1813-22
references.pmid: 4338122
references.citation: Biochemistry. 1974 Feb 26;13(5):1014-21
references.pmid: 4360349
references.citation: J Biochem. 1973 Aug;74(2):401-3
references.pmid: 4761329
references.citation: Proc Soc Exp Biol Med. 1971 Dec;138(3):952-8
references.pmid: 5131637
references.citation: Prog Hematol. 1966;5:204-45
references.pmid: 5337570
references.citation: J Immunol. 1970 Oct;105(4):802-11
references.pmid: 5470521
references.citation: S Afr Med J. 1970 Nov 14;44(45):1311-2
references.pmid: 5489601
references.citation: J Clin Invest. 1968 May;47(5):1172-80
references.pmid: 5645860
references.citation: Thromb Diath Haemorrh. 1965 Nov 15;14(3-4):387-400
references.pmid: 5865602
references.citation: J Physiol. 1958 Nov 10;144(1):1-22
references.pmid: 13599105
references.citation: Ann N Y Acad Sci. 1964 Aug 27;116:855-65
references.pmid: 14212858
references.citation: Thromb Diath Haemorrh. 1959 Sep 1;3:593-603
references.pmid: 14427142
references.citation: J Clin Invest. 1975 May;55(5):1082-9
references.pmid: 16695963